How did Amneal's revenue and expenses trend in Q4 2024 compared to previous quarters?

Amneal Pharmaceuticals (AMRX) demonstrated a clear upward trend in revenue and a slight increase in expenses from Q1 to Q4 of 2024: 1. **Revenue Trend**: - Q1 2024: $659.19 million - Q2 2024: $1.36 billion - Q3 2024: $2.06 billion - Q4 2024: $2.79 billion - This indicates a strong growth in revenue over the course of the year, with each quarter's revenue surpassing the previous one. 2. **Expense Trend**: - Q1 2024: No data was provided for expenses. - Q2 2024: No data was provided for expenses. - Q3 2024: No data was provided for expenses. - Q4 2024: Data was not provided for total expenses. - However, the absence of expense data for Q1, Q2, and Q3 suggests that only the Q4 figures were reported. Without Q1, Q2, and Q3 data, a direct comparison of expense trends is not possible. 3. **Growth Analysis**: - From Q1 to Q4, revenue grew from $659.19 million to $2.79 billion, indicating a significant increase in the company's income over the course of the year. - The fact that Q4 revenue was higher than Q3 revenue suggests that the company's performance improved in the final quarter of the year. In conclusion, Amneal Pharmaceuticals experienced robust growth in revenue from Q1 to Q4 2024, with the peak revenue occurring in Q4. The trend of increasing revenue indicates a strong financial performance and suggests that the company's business strategies are effective in generating income. However, the lack of expense data for Q1, Q2, and Q3 prevents a comprehensive analysis of the company's profitability trend over the same period.